Clonal selection of CD56+ t(8;21) AML blasts: Further suggestion of the adverse clinical significance of this biological marker?

British Journal of Haematology

Volumn 107, Issue 2, 1999, Pages 381-383

  Daniels, Jasmine T ^a   Davis, Brad J ^a   Houde McGrail, Lisa ^a   Byrd, John C ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute mylogenous leukaemia; CD56; Chromosomal translocation; Clonal selection; Neural cell adhesion molecule

Indexed keywords

BIOLOGICAL MARKER; CD56 ANTIGEN; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; CLONE; DISEASE ASSOCIATION; FEMALE; HUMAN; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032735431     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01711.x     Document Type: Article

References (10)

1. Baer, M.R., Stewart, C.C., Lawrence, D., Arthur, D.C., Byrd, J.C., Davey, F.R., Schiffer, C.A. & Bloomfield, C.D. (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood, 90, 1643-1648.
2. Bloomfield, C.D., Lawrence, D., Arthur, D.C., Berg, D.T., Schiffer, C.A. & Mayer, R.J. (1994) Curative impact of intensification with high-dose cytarabine in acute myeloid leukemia varies by cytogenetic group. Blood, 84, (Suppl. 1), abstract 111a.
3. Bloomfield, C.D., Lawrence, D., Byrd, J.C., Carroll, A., Pettenati, M.J., Tantravahi, R., Patil, S.R., Davey, F.R., Berg, D.T., Schiffer, C.A., Arthur, D.C. & Mayer, R.J. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Research, 58, 4173-4179.
4. Byrd, J.C., Dodge, R.K., Carroll, A., Baer, M.R., Edwards, C., Stamberg, J., Qumsiyeh, M., Moore, J.O., Mayer, R.J., Schiffer, C.A. & Bloomfield, C.D. (1998) Patients with t(8;21)(q22;q22) and AML have a superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. Blood, 92, (Suppl. 1), abstract 1282.
5. Byrd, J.C., Weiss, R.B., Arthur, D.C., Lawrence, D., Baer, M.R., Davey, F., Trikha, E.S., Carroll, A.J., Tantravahi, R., Qumsiyeh, M., Patil, S.R., Moore, J.O., Mayer, K.J., Schiffer, C.A. & Bloomfield, C.D. (1997) Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. Journal of Clinical Oncology, 15, 466-475.
6. Campana, D., Coustan-Smith, E. & Janossy, G. (1990) The immunologic detection of minimal residual disease in acute leukemia. Blood, 76, 163-171.
7. Macedo, A., Orfao, A., Gonzalez, M., Viridales, M.B., Lopez-Berges, M.C., Martinez, A. & San Miguel, J.F. (1995a) Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease. Leukemia, 9, 993-998.
8. Macedo, A., Orfao, A., Viridales, M.B., Lopez-Berges, M.C., Valverde, B., Gonzalez, M., Caballero, M.D., Ramos, F., Martinez, M. & Fernandez-Calvo, J. (1995b) Characterization of aberrant phenotypes in acute myeloblastic leukemia. Annals of Hematology, 70, 189-194.
9. Murray, C.K., Estey, E., Paietta, E., Howard, R.S., Edenfield, W.J., Pierce, S., Mann, K.P., Bolan, C. & Byrd, J.C. (1999) CD56 expression in APL: a possible indication of poor treatment outcome? Journal of Clinical Oncology, 17, 293-297.
10. San Miguel, J.F., Martinez, A., Macedo, A., Viridales, M.B., Lopez-Berges, C., Gonzalez, M., Caballero, D., Diaz Mediavilla, J. & Orfao, A. (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood, 90, 2465-2670.